NYMC Faculty Publications
Vesicular Monoamine Transporter Type 2 Inhibition Can Lead to Effective and Tolerable Management of Tardive Dyskinesia
DOI
10.1136/eb-2017-102825
Journal Title
Evidence Based Mental Health
First Page
e12
Document Type
Article
Publication Date
August 2018
Department
Psychiatry and Behavioral Sciences
Recommended Citation
Citrome, L. L. (2018). Vesicular Monoamine Transporter Type 2 Inhibition Can Lead to Effective and Tolerable Management of Tardive Dyskinesia. Evidence Based Mental Health, 21 (3), e12. https://doi.org/10.1136/eb-2017-102825
COinS
